Clinical Trials Logo

Clinical Trial Summary

The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.


Clinical Trial Description

The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients, and developing a IgAN database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum and urine), complications, drug information at the baseline will be collected. Patients will be follow-up every one year, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the clinical events at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), ESRD (defined as initiation of dialysis or kidney transplantation) and hospitalization for any cause. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and ESRD for IgAN patients will be compared using the IgAN database. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03001947
Study type Observational [Patient Registry]
Source Sun Yat-sen University
Contact Xueqing Yu, M.D. & Ph.D
Email yuxq@mail.sysu.edu.cn
Status Recruiting
Phase
Start date November 2012
Completion date December 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05016323 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. Phase 2
Withdrawn NCT02433236 - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Phase 2
Recruiting NCT02231125 - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Phase 4
Completed NCT01502579 - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data N/A
Not yet recruiting NCT01203007 - Diet Intervention in Food Sensitive Patients With IgA Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00657059 - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Phase 3
Recruiting NCT04684745 - Open-Label Extension Study of BION-1301 in IgA Nephropathy Phase 2
Completed NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects Phase 1
Withdrawn NCT02052219 - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Phase 3
Completed NCT02112838 - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Phase 2
Completed NCT00767221 - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Phase 2
Recruiting NCT04438603 - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Terminated NCT04905212 - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Phase 2
Terminated NCT04042623 - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy Phase 2
Recruiting NCT03633864 - Fecal Microbiota Transplantation for Refractory IgA Nephropathy Phase 2
Not yet recruiting NCT06454110 - Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) Phase 2
Recruiting NCT02954419 - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Completed NCT01224028 - A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients Phase 2